Europe Pneumococcal Vaccines Market Industry Trends and Forecast to 2034: Segmented by (Type, Age, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Overview
Market Dashboard
Europe · 2024–2034 · placeholder estimates
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the
full report.
Estimate 2024$1.56 BnPlaceholder estimate
Estimate 2025$1.63 Bn16.1% of the global market
Projected 2034$2.46 Bn 51.2%Adds $834.5 Mn over 9 forecast years
CAGR 2025–20344.7%Faster than 25% of 180 Pharmaceuticals markets here
Key players5
Europe is 16.12% of the global market.
Among regions, the largest is North America at $5.62 Bn.
11 in EuropeSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Europe. Retrieved 12 Nov 2026.
Formats
PDF, PPTX, XLSX
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
The Europe Pneumococcal Vaccines Market Analysis Executive Summary
Pneumococcal vaccines protect against pneumonia, meningitis and blood infections caused by pneumococcus bacteria.
Key segments of the pneumococcal Vaccines market include type (Conjugate Vaccines and Polysaccharide Vaccines) and age (Infants, Older Adults and At-Risk Adults).
Europe Pneumococcal Vaccines market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.
Europe Pneumococcal Vaccines Market Dynamics
Market Growth Drivers
Rising antimicrobial resistance, outbreaks of new and returning diseases, climate change spreading infections and strong global funding for prevention are driving the pneumococcal Vaccines market.
Opportunity
New vaccines, rapid tests and public-private funding for neglected diseases give the pneumococcal Vaccines market room to grow, especially in Asia, Africa and Latin America.
Market Restraints
Low prices in poorer markets, weak returns for new antibiotics, vaccine hesitancy and cold-chain problems hold back the pneumococcal Vaccines market.
Competitive Landscape for Pneumococcal Vaccines Market in Europe
The pneumococcal Vaccines market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Healthcare Policies and Regulatory Landscape for Pneumococcal Vaccines Market in Europe
Pneumococcal Vaccines in Europe: rules, payment and research
In the EU, many new medicines are authorised once for every member state by the European Commission, after review by the European Medicines Agency (EMA).[1] In the countries we cover here, medicines are approved by ANSM (France)[2], BfArM (Germany)[3], AIFA (Italy)[4], Ministry of Health (Russia)[5], AEMPS (Spain)[6] and MHRA (UK)[7]. Each country runs its own health system and decides prices and reimbursement; since January 2025, EU countries also share joint clinical assessments of some new medicines.[8] ClinicalTrials.gov lists 11 studies on Pneumococcal Vaccines that are recruiting, active or about to start in Europe.[9]
[9]ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Europe. Retrieved 12 Nov 2026.
Policy changes and Reimbursement scenario
Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for pneumococcal Vaccines. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Europe.
2.2 Market Size, Growth Prospects and Key findings
3 Market Dynamics
3.1 Market Growth Drivers Analysis
3.2 Market Restraints Analysis
4 Market Segmentation
4.1 By Type
4.2 By Age
4.3 By End User
5 By Market Share
5.1 Market Analysis, Insights and Forecast – By Revenue
6 Competitive Landscape
6.1 Major Top Market Players Products in Pipeline
6.2 R&D Initiatives
6.3 Notable recent Deals
6.3.1 Strategic Divestments
6.3.2 Mergers & Acquisitions
6.3.3 Partnerships
6.3.4 Joint Ventures
7 Key Company Profiles
7.1 Pfizer
7.2 Merck & Co.
7.3 GSK
7.4 Serum Institute of India
7.5 Vaxcyte
8 Healthcare Policies and Regulatory Landscape
8.1 Policy changes and Reimbursement scenario
8.2 Government Initiatives / Intervention programs
The pneumococcal Vaccines market can be segmented based on various criteria, including type, age and end user. Here's a breakdown of the market segmentation
Other companies that free public records show in this market: trials they lead, US approvals and WHO prequalification. They are not part of our key players research. Each count opens its source.
Also active in this area, from free public records
Source: ClinicalTrials.gov, Active studies (recruiting, about to start or running) each company leads, found with this market's trial search, worldwide. Retrieved 13 Nov 2026.
Source: Drugs@FDA, US approvals each company holds for medicines on the market whose FDA label lists this use. Retrieved 13 Nov 2026.
Source: WHO Prequalification, Vaccines, tests and medicines on the WHO prequalified lists that match this market. Retrieved 13 Nov 2026.
Beyond the market numbers
Research, trials and patients
What doctors and scientists are doing in Pneumococcal Vaccines right now, from free public sources.
Clinical trials
11 active trials in UK, Germany, France, Italy, Spain and Russia
Recruiting, about to start, or running now. Counted across the 6 countries we report on in Europe.
Sources:PubMed (US National Library of Medicine),
ClinicalTrials.gov.
Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
How big is the Pneumococcal Vaccines market in Europe?
Placeholder estimate: about $1.63 Bn in 2025, rising to about $2.46 Bn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Pneumococcal Vaccines market in Europe growing?
Placeholder estimate: about 4.7% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Pneumococcal Vaccines market report cover?
The report splits the market by type (Conjugate Vaccines, Polysaccharide Vaccines), age (Infants, Older Adults, At-Risk Adults) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the Pneumococcal Vaccines market?
Key players include Pfizer Inc., Merck & Co., Inc., GSK PLC, Serum Institute of India and Vaxcyte.
What is driving the Pneumococcal Vaccines market?
Rising antimicrobial resistance, outbreaks of new and returning diseases, climate change spreading infections and strong global funding for prevention are driving the pneumococcal Vaccines market.
Who regulates Pneumococcal Vaccines in Europe?
In the EU, many new medicines are authorised once for every member state by the European Commission, after review by the European Medicines Agency (EMA). Source: European Medicines Agency. Checked 14 Nov 2026.
How is healthcare paid for in Europe?
Each country runs its own health system and decides prices and reimbursement; since January 2025, EU countries also share joint clinical assessments of some new medicines. Source: European Commission, health technology assessment. Checked 14 Nov 2026.
How many clinical trials on Pneumococcal Vaccines are running in Europe?
11 studies are recruiting, active or about to start in Europe, counted across the 6 countries we report on there, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Europe. Retrieved 12 Nov 2026.
How much research is published on Pneumococcal Vaccines?
PubMed lists 657 papers on Pneumococcal Vaccines added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
US
Canada
China
Japan
Germany
Italy
France
UK
Brazil
India
Saudi Arabia
Ecuador
Spain
Mexico
Russia
Australia
New Zealand
South Africa
UAE
Egypt
Philippines
Malaysia
Hong Kong
Thailand
Singapore
Kenya
Aurobindo Pharma
Sanofi
Hikma Pharmaceuticals PLC